30 Day Trial
BARE BONES logo

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

NeoCart Phase 3 Clinical Trial Enrollment Update -

Histogenics has now enrolled ~3/4 (183) of 245 patients required to complete enrollment of its ongoing NeoCart Phase III clinical trial, which is being conducted under a Special Protocol Assessment (SPA) with FDA.

This is an increase from 50% completion announced in mid-1Q16, after the 4Q15 amendment to the trial protocol to expand the eligible patient population.

A recent financing will fund the company through top-line data read-out in mid-2018.

The Phase III trial is designed to evaluate safety and efficacy of NeoCart tissue-engineered cartilage as a first-line therapy for full thickness knee cartilage defects in skeletally mature adults vs. microfracture, the standard of care.

Sources: Histogenics Corporation; ORTHOWORLD Inc.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.